R Harpaz
Overview
Explore the profile of R Harpaz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
589
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harpaz R, DuMochel W, Shah N
Clin Pharmacol Ther
. 2015 Nov;
99(3):268-70.
PMID: 26575203
Big Data holds the promise of fundamentally transforming the manner in which adverse drug reactions can be identified and evaluated. This commentary discusses new data sources that are envisioned to...
2.
Goldman Boue T, Harpaz R, Fineberg J, Bouchbinder E
Soft Matter
. 2015 Apr;
11(19):3812-21.
PMID: 25857951
Highly-deformable materials, from synthetic hydrogels to biological tissues, are becoming increasingly important from both fundamental and practical perspectives. Their mechanical behaviors, in particular the dynamics of crack propagation during failure,...
3.
White R, Harpaz R, Shah N, DuMouchel W, Horvitz E
Clin Pharmacol Ther
. 2014 Apr;
96(2):239-46.
PMID: 24713590
The promise of augmenting pharmacovigilance with patient-generated data drawn from the Internet was called out by a scientific committee charged with conducting a review of the current and planned pharmacovigilance...
4.
Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah N
Clin Pharmacol Ther
. 2013 Jun;
94(3):313.
PMID: 23756371
No abstract available.
5.
LePendu P, Iyer S, Bauer-Mehren A, Harpaz R, Mortensen J, Podchiyska T, et al.
Clin Pharmacol Ther
. 2013 Apr;
93(6):547-55.
PMID: 23571773
With increasing adoption of electronic health records (EHRs), there is an opportunity to use the free-text portion of EHRs for pharmacovigilance. We present novel methods that annotate the unstructured clinical...
6.
Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah N
Clin Pharmacol Ther
. 2013 Apr;
93(6):539-46.
PMID: 23571771
Signal-detection algorithms (SDAs) are recognized as vital tools in pharmacovigilance. However, their performance characteristics are generally unknown. By leveraging a unique gold standard recently made public by the Observational Medical...
7.
Harpaz R, DuMouchel W, Shah N, Madigan D, Ryan P, Friedman C
Clin Pharmacol Ther
. 2012 May;
91(6):1010-21.
PMID: 22549283
An important goal of the health system is to identify new adverse drug events (ADEs) in the postapproval period. Datamining methods that can transform data into meaningful knowledge to inform...
8.
Joesoef M, Leung J, Harpaz R, Bialek S
Vaccine
. 2011 Jan;
29(11):2008-9.
PMID: 21216316
No abstract available.
9.
Harpaz R, Perez H, Chase H, Rabadan R, Hripcsak G, Friedman C
Clin Pharmacol Ther
. 2010 Dec;
89(2):243-50.
PMID: 21191383
In this article, we present a new pharmacovigilance data mining technique based on the biclustering paradigm, which is designed to identify drug groups that share a common set of adverse...
10.
Seward J, Galil K, Damon I, Norton S, Rotz L, Schmid S, et al.
Clin Infect Dis
. 2004 Nov;
39(10):1477-83.
PMID: 15546084
Concerns that smallpox, an eradicated disease, might reappear because of a bioterror attack and limited experience with smallpox diagnosis in the United States prompted us to design a clinical algorithm....